Tuberculosis Cohort Avicenne Hospital

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 12, 2022

Keywords

ClinConnect Summary

The Tuberculosis Cohort Avicenne Hospital study aims to learn more about tuberculosis (TB), especially in people living in the Seine-Saint-Denis area of France, which has been heavily affected by this disease. TB is a serious infection that can lead to death, and understanding why some patients have a harder time recovering is important for improving treatment. This study will include patients diagnosed with either pulmonary (lung) or extra-pulmonary TB over a period of at least five years, allowing researchers to gather valuable information about the disease and its treatment.

To participate in this study, individuals must be newly diagnosed with TB and receiving treatment at one of the participating centers. They need to have a confirmed diagnosis through tests or strong evidence that they have the disease. However, those who have already been on TB treatment for more than seven days or are involved in other research studies cannot join. Participants can expect regular follow-ups for at least a year after their initial treatment. This research is important as it seeks to find better ways to manage and control tuberculosis, especially in communities that are most affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Tuberculosis out- or in-patient newly treated in one of the inclusion centers for pulmonary or extra-pulmonary
• • Tu confirmed bacteriologically (direct examination, Gen-eXpert MTB/RIF and/or positive culture), suggestive histology (epithelioid gigantocellular granuloma with or without caseous necrosis), or strong clinical suspicion of tuberculosis, even if not yet biologically confirmed but with
• • A decision to introduce treatment.
• Exclusion Criteria:
• • opposition to participate in the study, anti-tuberculosis treatment for more than 7 days at the inclusion visit and participation in another research protocol.